Reply to “Letter to the Editor on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study’”, by V. C. G. Tjan-Heijnen, P. E. Postmus &A. Ardizzoni(Ann Oncol 2002; 13: 485–486)

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study

Annals of Oncology ◽

10.1023/a:1012545507920 ◽

2001 ◽

Vol 12 (10) ◽

pp. 1359-1368 ◽

Cited By ~ 80

Author(s):

V.C.G. Tjan-Heijnen ◽

P.E. Postmus ◽

A. Ardizzoni ◽

Ch. Manegold ◽

J. Burghouts ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Editorial comments on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study’

Annals of Oncology ◽

10.1023/a:1012579018035 ◽

2001 ◽

Vol 12 (10) ◽

pp. 1339-1340 ◽

Cited By ~ 5

Author(s):

P.A. Bunn

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Reply to the article “Editorial comment on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study’”, by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339–1340)

Annals of Oncology ◽

10.1093/annonc/mdf138 ◽

2002 ◽

Vol 13 (3) ◽

pp. 485-486 ◽

Cited By ~ 3

Author(s):

V.C.G. Tjan-Heijnen ◽

P.E. Postmus ◽

A. Ardizzoni

Keyword(s):

Lung Cancer ◽

Editorial Comment ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)

Annals of Oncology ◽

10.1093/annonc/mdg073 ◽

2003 ◽

Vol 14 (2) ◽

pp. 248-257 ◽

Cited By ~ 19

Author(s):

V.C.G. Tjan-Heijnen ◽

S. Caleo ◽

P.E. Postmus ◽

A. Ardizzoni ◽

J.T.M. Burghouts ◽

...

Keyword(s):

Lung Cancer ◽

Economic Evaluation ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps10142 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS10142-TPS10142

Author(s):

Li Zhang ◽

Ting Zhou ◽

Yuxiang Ma ◽

Yunpeng Yang ◽

Wenfeng Fang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone

Annals of Oncology ◽

10.1093/annonc/mdm061 ◽

2007 ◽

Vol 18 (5) ◽

pp. 903-908 ◽

Cited By ~ 14

Author(s):

S. Novello ◽

P. Bruzzi ◽

C. Barone ◽

R. Buosi ◽

A. Masotti ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

O-161 Efficacy of antibacterial prophylaxis following myelosuppressive chemotherapy: Results from a randomised, double-blind, placebo-controlled trial of levofloxacin including 220 small cell lung cancer patients

Lung Cancer ◽

10.1016/s0169-5002(05)80295-8 ◽

2005 ◽

Vol 49 ◽

pp. S55

Author(s):

L. Billingham ◽

M. Cullen ◽

N. Steven ◽

C. Gaunt ◽

M. Hastings

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Controlled Trial ◽

Small Cell ◽

Antibacterial Prophylaxis ◽

Small Cell Lung ◽

Double Blind ◽

Myelosuppressive Chemotherapy ◽

Double Blind Placebo ◽

Lung Cancer Patients

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181da36db ◽

2010 ◽

Vol 5 (7) ◽

pp. 1042-1047 ◽

Cited By ~ 6

Author(s):

Nobuyuki Yamamoto ◽

Yutaka Nishiwaki ◽

Shunichi Negoro ◽

Haiyi Jiang ◽

Yohji Itoh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Control ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)

European Journal of Cancer ◽

10.1016/j.ejca.2015.04.026 ◽

2015 ◽

Vol 51 (12) ◽

pp. 1511-1528 ◽

Cited By ~ 17

Author(s):

Mary E.R. O’Brien ◽

Rabab Gaafar ◽

Baktiar Hasan ◽

Jessica Menis ◽

Tanja Cufer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Lung Cancer Patients ◽

Cancer Group ◽

Phase Iii Study ◽

Line Chemotherapy